Contact
searchSearch
HMP Global
Login

Interactive Features

Quiz
Allogeneic Stem Cell Transplantation for R/R CLL
09/11/2025
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with high-risk or R/R chronic lymphocytic leukemia, including those previously treated with pathway inhibitors, allogeneic hematopoietic stem cell transplantation demonstrated improved outcomes.
True or False: For patients with...
09/11/2025
Oncology
Quiz
MRD as End Point in CLL Clinical Trials
11/22/2024
True or False: A systematic review and meta-analysis suggest that assessing MRD status as a meaningful end point in clinical trials as a substitute for PFS may improve trial efficiency and lead to possiblities for faster drug registration....
True or False: A systematic review and meta-analysis suggest that assessing MRD status as a meaningful end point in clinical trials as a substitute for PFS may improve trial efficiency and lead to possiblities for faster drug registration....
True or False: A systematic...
11/22/2024
Oncology
Quiz
PFS for Patients With CLL/SLL With Frontline Ibrutinib Treatment
11/21/2024
True or False: In a final analysis of the RESONATE 2 study, the median progression-free survival with frontline ibrutinib treatment was 8.9 years for patients with CLL/SLL.
True or False: In a final analysis of the RESONATE 2 study, the median progression-free survival with frontline ibrutinib treatment was 8.9 years for patients with CLL/SLL.
True or False: In a final...
11/21/2024
Oncology
Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Adding Venetoclax to High-Risk Chronic Lymphocytic Leukemia Treatment
10/31/2023
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax therapy among patients with high-risk chronic lymphocytic leukemia who had received at least ___ months or more of ibrutinib treatment achieved a high rate of undetectable measurable residual disease (U-MRD) in the...
The addition of venetoclax...
10/31/2023
Oncology
Quiz
Venetoclax for CLL With High-Risk Features
10/05/2023
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax therapy yielded high rates of undetectable measurable residual disease (U-MRD) in the bone marrow among patients with CLL who had received ibrutinib for ≥12 months and had high-risk features, including ___.
The addition of venetoclax...
10/05/2023
Oncology
Quiz
Ibrutinib Plus Venetoclax Combination for Previously Untreated CLL
09/01/2023
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the phase 3 GLOW trial indicated that ibrutinib plus venetoclax treatment did not improve progression-free survival compared to treatment with chlorambucil and obinutuzumab among older patients with previously...
True or False: Results of the...
09/01/2023
Oncology
Quiz
FDA Approval of Zanubrutinib for CLL/SLL
05/23/2023
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib for CLL or SLL based on efficacy results from the ALPINE trial, which indicated that the overall response rate among patients who received this treatment was ____.
The FDA approved zanubrutinib...
05/23/2023
Oncology
Quiz
Quiz: Overall Survival Rate of Venetoclax Plus Rituximab Treatment in Patients With Relapsed/Refractory CLL
12/01/2022
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival rate of venetoclax plus rituximab treatment in patients with relapsed/refractory CLL at 3 years following cessation, according to a 5-year update of a phase 3 trial? 
What was the overall survival...
12/01/2022
Oncology

Recent News

News
Genotype-Guided Therapy Demonstrates High Response and Survival Rates for Patients With R/R DLBCL
09/26/2025
Emily Estrada
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE combined with genotype-guided therapy for the treatment of relapsed/refractory diffuse large B-cell lymphoma demonstrated clinical efficacy and safety in a phase 2 trial.
The implementation of R-ICE...
09/26/2025
Oncology
News
PD-1/PD-L1 Inhibitor Monotherapy Demonstrates Accceptable Safety, Limited Efficacy for R/R DLBCL
09/26/2025
Emily Estrada
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large B-cell lymphoma with PD-1/PD-L1 inhibitors alone showed consistent safety but limited efficacy, while combination treatment with CAR T-cell therapy demonstrated potential improved outcomes.
Treatment of R/R diffuse large...
09/26/2025
Oncology
News
Polatuzumab-Based Regimens Demonstrate Promising Efficacy for R/R DLBCL Compared to Traditional Salvage Therapies
09/26/2025
Emily Estrada
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional salvage therapies, polatuzumab vedotin and zanubrutinib combined with rituximab or obinutuzumab demonstrated encouraging clinical efficacy for patients with relapsed/refractory diffuse large B-cell lymphoma.
Compared with traditional...
09/26/2025
Oncology
FDA Approval
FDA Approves Imlunestrant for Patients With ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
09/25/2025
Stephanie Holland
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved imlunestrant for patients with ER-positive, HER2-negative advanced or metastatic breast cancer harboring ESR1 mutations.
The FDA has approved...
09/25/2025
Oncology
News
Pexidartinib Shows Durable Response Among Patients with Tenosynovial Giant Cell Tumors
09/25/2025
Allison Casey
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained clinical benefit among patients with tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to surgery.
Pexidartinib showed sustained...
09/25/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
News
First-Line mFOLFIRINOX, S-IROX Fail to Improve Survival Among Patients With Recurrent or Metastatic Pancreatic Cancer
09/23/2025
Stephanie Holland
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3 GENERATE study demonstrated that neither mFOLFIRINOX nor S-IROX improved survival results compared to nab-paclitaxel plus gemcitabine among patients with recurrent or metastatic pancreatic cancer in the first-line...
Results from the phase 2/3...
09/23/2025
Oncology
News
Novel Anti-CSF1 Receptor Antibody for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial, the novel anti-CSF1 receptor monoclonal antibody, AMB-05X, was found to have favorable pharmacokinetics, pharmacodynamics, efficacy, and safety among patients with tenosynovial giant cell tumors.
According to a phase 2a trial,...
09/23/2025
Oncology
News
Adverse Events With Pexidartinib for Patients With Tenosynovial Giant Cell Tumor
09/23/2025
Allison Casey
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the FDA Adverse Events Reporting System (FAERS) database, the overall safety profile of pexidartinib was generally consistent with the clinical trial findings.
According to an analysis of the...
09/23/2025
Oncology
News
Trifluridine/Tipiracil Plus Bevacizumab Escalation Demonstrates Promise Among Patients With Advanced or Unresectable Metastatic Colorectal Cancer
09/22/2025
Stephanie Holland
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the phase 2 E-BiTS study, intrapatient escalation of biweekly trifluridine/tipiracil plus bevacizumab demonstrated promising efficacy and safety among patients with advanced or unresectable metastatic colorectal...
According to results from the...
09/22/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use